Abstract
Objective: This study was undertaken to evaluate the relationship between GPR30, classical steroidal receptor expression, and clinical outcome in patients with endometrial carcinoma. Study Design: Immunohistochemistry was used to investigate the expression of GPR30, estrogen, progesterone, epidermal growth factor receptors and Ki-67 in 47 consecutive consenting patients with endometrial carcinoma diagnosed between 1997 and 2001. Results were correlated with clinical and pathologic predictors of adverse outcome and survival. Results: GPR30 correlated positively with epidermal growth factor receptor (P = .005), but negatively with progesterone (P = .05) receptor expression. GPR30 overexpression occurred more frequently in tumors with deep myometrial invasion, high-grade, biologically aggressive histologic subtypes, and advanced stage. In patients with GPR30 overexpression, survival was significantly poorer (65.2% vs 100%, P = .005). Conclusion: GPR30 represents an alternative estrogen-responsive receptor that is overexpressed in tumors where estrogen and progesterone receptors are downregulated, and in high-risk endometrial cancer patients with lower survival rates.
Original language | English (US) |
---|---|
Pages (from-to) | 386.e1-386.e11 |
Journal | American journal of obstetrics and gynecology |
Volume | 196 |
Issue number | 4 |
DOIs | |
State | Published - Apr 2007 |
Externally published | Yes |
Keywords
- GPR30
- endometrial carcinoma
- estrogen receptor
- progesterone receptor
- survival
ASJC Scopus subject areas
- Obstetrics and Gynecology